[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fc9181rmeg2LneJYH51AHx6Sg6fCCJy9UOPfc5hUyLYI":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":9,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":30,"phaseBuckets":31,"rows":38},"Brno University Hospital",[4],90,false,15,0,33970,83,[13,16,18,20,22,24,26,28],{"name":14,"count":15},"Emergence Delirium",2,{"name":17,"count":15},"COVID-19 Pneumonia",{"name":19,"count":15},"Multiple Sclerosis",{"name":21,"count":15},"Covid19",{"name":23,"count":15},"Enteral Feeding Intolerance",{"name":25,"count":15},"Education",{"name":27,"count":15},"Anaesthesia",{"name":29,"count":15},"Brain Death",[],[32,33,34,35,36,37],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[39,70,97,124,142,167,192,222,240,258,276,294,312],{"intervention":40,"totalTrials":41,"cells":42},"Fibrinogen Concentrate Human",1,{"EARLY_PHASE1":43,"PHASE1":45,"PHASE2":47,"PHASE3":49,"PHASE4":51,"NA":68},{"trials":44,"activeCount":9},[],{"trials":46,"activeCount":9},[],{"trials":48,"activeCount":9},[],{"trials":50,"activeCount":9},[],{"trials":52,"activeCount":9},[53],{"nctId":54,"briefTitle":55,"status":56,"phases":57,"primaryCompletion":58,"completion":59,"start":60,"enrollment":61,"conditions":62,"interventions":67},"NCT05391412","Effect of Prophylactic Fibrinogen Concentrate In Scoliosis Surgery","UNKNOWN",[36],"2023-07-30","2023-09-30","2022-06-06",32,[63,64,65,66],"Fibrinogen","Spine Deformity","Coagulopathy, Consumption","Bleeding",[40],{"trials":69,"activeCount":9},[],{"intervention":71,"totalTrials":41,"cells":72},"Dexamethasone",{"EARLY_PHASE1":73,"PHASE1":75,"PHASE2":77,"PHASE3":79,"PHASE4":81,"NA":95},{"trials":74,"activeCount":9},[],{"trials":76,"activeCount":9},[],{"trials":78,"activeCount":9},[],{"trials":80,"activeCount":9},[],{"trials":82,"activeCount":9},[83],{"nctId":84,"briefTitle":85,"status":86,"phases":87,"primaryCompletion":88,"completion":89,"start":90,"enrollment":91,"conditions":92,"interventions":94},"NCT04663555","Effect of Two Different Doses of Dexamethasone in Patients With ARDS and COVID-19","COMPLETED",[36],"2022-03-09","2023-02-23","2021-02-02",235,[21,93],"ARDS",[71],{"trials":96,"activeCount":9},[],{"intervention":98,"totalTrials":41,"cells":99},"Rocuronium + sugammadex",{"EARLY_PHASE1":100,"PHASE1":102,"PHASE2":104,"PHASE3":106,"PHASE4":108,"NA":122},{"trials":101,"activeCount":9},[],{"trials":103,"activeCount":9},[],{"trials":105,"activeCount":9},[],{"trials":107,"activeCount":9},[],{"trials":109,"activeCount":9},[110],{"nctId":111,"briefTitle":112,"status":86,"phases":113,"primaryCompletion":114,"completion":114,"start":115,"enrollment":116,"conditions":117,"interventions":120},"NCT01718236","Modern Myorelaxation Procedure and Reversal of Neuromuscular Blockade With General Anesthesia for Caesarean Section",[36],"2015-01","2012-09",500,[118,119],"Caesarean Section","Pregnancy",[98,121],"Succinylcholine + Neostigmine",{"trials":123,"activeCount":9},[],{"intervention":121,"totalTrials":41,"cells":125},{"EARLY_PHASE1":126,"PHASE1":128,"PHASE2":130,"PHASE3":132,"PHASE4":134,"NA":140},{"trials":127,"activeCount":9},[],{"trials":129,"activeCount":9},[],{"trials":131,"activeCount":9},[],{"trials":133,"activeCount":9},[],{"trials":135,"activeCount":9},[136],{"nctId":111,"briefTitle":112,"status":86,"phases":137,"primaryCompletion":114,"completion":114,"start":115,"enrollment":116,"conditions":138,"interventions":139},[36],[118,119],[98,121],{"trials":141,"activeCount":9},[],{"intervention":143,"totalTrials":41,"cells":144},"ofatumumab plus dexamethasone",{"EARLY_PHASE1":145,"PHASE1":147,"PHASE2":149,"PHASE3":161,"PHASE4":163,"NA":165},{"trials":146,"activeCount":9},[],{"trials":148,"activeCount":9},[],{"trials":150,"activeCount":9},[151],{"nctId":152,"briefTitle":153,"status":86,"phases":154,"primaryCompletion":155,"completion":155,"start":156,"enrollment":157,"conditions":158,"interventions":160},"NCT01310101","Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia",[34],"2015-02","2011-04",33,[159],"Chronic Lymphocytic Leukemia",[143],{"trials":162,"activeCount":9},[],{"trials":164,"activeCount":9},[],{"trials":166,"activeCount":9},[],{"intervention":168,"totalTrials":41,"cells":169},"remifentanil",{"EARLY_PHASE1":170,"PHASE1":172,"PHASE2":174,"PHASE3":176,"PHASE4":178,"NA":180},{"trials":171,"activeCount":9},[],{"trials":173,"activeCount":9},[],{"trials":175,"activeCount":9},[],{"trials":177,"activeCount":9},[],{"trials":179,"activeCount":9},[],{"trials":181,"activeCount":9},[182],{"nctId":183,"briefTitle":184,"status":86,"phases":185,"primaryCompletion":114,"completion":186,"start":187,"enrollment":188,"conditions":189,"interventions":191},"NCT02447757","Efficacy and Satisfaction With Remifentanil Analgesia in Parturients During the Childbirth",[],"2016-02","2010-01",66,[190],"Complication of Labor and\u002For Delivery",[168],{"intervention":193,"totalTrials":41,"cells":194},"Rocuronium",{"EARLY_PHASE1":195,"PHASE1":197,"PHASE2":199,"PHASE3":201,"PHASE4":203,"NA":205},{"trials":196,"activeCount":9},[],{"trials":198,"activeCount":9},[],{"trials":200,"activeCount":9},[],{"trials":202,"activeCount":9},[],{"trials":204,"activeCount":9},[],{"trials":206,"activeCount":9},[207],{"nctId":208,"briefTitle":209,"status":86,"phases":210,"primaryCompletion":211,"completion":212,"start":213,"enrollment":188,"conditions":214,"interventions":216},"NCT02546843","Depth of Neuromuscular Blockade and the Perioperative Conditions in Laparoscopic Surgery in Pediatric Population",[37],"2018-09","2019-05","2015-12",[215],"Neuromuscular Blockade",[193,217,218,219,220,221],"Cisatracurium","Nonspecific Neuromuscular Blockade reversal","Specific Neuromuscular Blockade reversal","maintaining the depth of neuromuscular blockade - rocuronium","maintaining the depth of neuromuscular blockade - cisatracurium",{"intervention":217,"totalTrials":41,"cells":223},{"EARLY_PHASE1":224,"PHASE1":226,"PHASE2":228,"PHASE3":230,"PHASE4":232,"NA":234},{"trials":225,"activeCount":9},[],{"trials":227,"activeCount":9},[],{"trials":229,"activeCount":9},[],{"trials":231,"activeCount":9},[],{"trials":233,"activeCount":9},[],{"trials":235,"activeCount":9},[236],{"nctId":208,"briefTitle":209,"status":86,"phases":237,"primaryCompletion":211,"completion":212,"start":213,"enrollment":188,"conditions":238,"interventions":239},[37],[215],[193,217,218,219,220,221],{"intervention":218,"totalTrials":41,"cells":241},{"EARLY_PHASE1":242,"PHASE1":244,"PHASE2":246,"PHASE3":248,"PHASE4":250,"NA":252},{"trials":243,"activeCount":9},[],{"trials":245,"activeCount":9},[],{"trials":247,"activeCount":9},[],{"trials":249,"activeCount":9},[],{"trials":251,"activeCount":9},[],{"trials":253,"activeCount":9},[254],{"nctId":208,"briefTitle":209,"status":86,"phases":255,"primaryCompletion":211,"completion":212,"start":213,"enrollment":188,"conditions":256,"interventions":257},[37],[215],[193,217,218,219,220,221],{"intervention":219,"totalTrials":41,"cells":259},{"EARLY_PHASE1":260,"PHASE1":262,"PHASE2":264,"PHASE3":266,"PHASE4":268,"NA":270},{"trials":261,"activeCount":9},[],{"trials":263,"activeCount":9},[],{"trials":265,"activeCount":9},[],{"trials":267,"activeCount":9},[],{"trials":269,"activeCount":9},[],{"trials":271,"activeCount":9},[272],{"nctId":208,"briefTitle":209,"status":86,"phases":273,"primaryCompletion":211,"completion":212,"start":213,"enrollment":188,"conditions":274,"interventions":275},[37],[215],[193,217,218,219,220,221],{"intervention":220,"totalTrials":41,"cells":277},{"EARLY_PHASE1":278,"PHASE1":280,"PHASE2":282,"PHASE3":284,"PHASE4":286,"NA":288},{"trials":279,"activeCount":9},[],{"trials":281,"activeCount":9},[],{"trials":283,"activeCount":9},[],{"trials":285,"activeCount":9},[],{"trials":287,"activeCount":9},[],{"trials":289,"activeCount":9},[290],{"nctId":208,"briefTitle":209,"status":86,"phases":291,"primaryCompletion":211,"completion":212,"start":213,"enrollment":188,"conditions":292,"interventions":293},[37],[215],[193,217,218,219,220,221],{"intervention":221,"totalTrials":41,"cells":295},{"EARLY_PHASE1":296,"PHASE1":298,"PHASE2":300,"PHASE3":302,"PHASE4":304,"NA":306},{"trials":297,"activeCount":9},[],{"trials":299,"activeCount":9},[],{"trials":301,"activeCount":9},[],{"trials":303,"activeCount":9},[],{"trials":305,"activeCount":9},[],{"trials":307,"activeCount":9},[308],{"nctId":208,"briefTitle":209,"status":86,"phases":309,"primaryCompletion":211,"completion":212,"start":213,"enrollment":188,"conditions":310,"interventions":311},[37],[215],[193,217,218,219,220,221],{"intervention":313,"totalTrials":41,"cells":314},"Neuromuscular Blocking Agent",{"EARLY_PHASE1":315,"PHASE1":317,"PHASE2":319,"PHASE3":321,"PHASE4":323,"NA":325},{"trials":316,"activeCount":9},[],{"trials":318,"activeCount":9},[],{"trials":320,"activeCount":9},[],{"trials":322,"activeCount":9},[],{"trials":324,"activeCount":9},[],{"trials":326,"activeCount":9},[327],{"nctId":328,"briefTitle":329,"status":86,"phases":330,"primaryCompletion":331,"completion":332,"start":333,"enrollment":334,"conditions":335,"interventions":336},"NCT03086915","Myorelaxation Practice in Paediatric Anesthesia",[],"2017-07-30","2017-08-01","2017-03-05",1650,[215],[313]]